
Private Equity Firms Cut Deal Activity 75% While Biotech Bets Double Amid Global Market Volatility
Tiger Global and SoftBank Vision Fund slashed deal activity 75-95% from 2021 peaks while Forbion Capital doubled biotech investments, exposing sharp strategic splits in global private equity. The divergence reflects competing bets on market conditions, with cautious firms bracing for turbulence and opportunistic players targeting distressed valuations. Analysts project the S&P 500 could fall to 3,500 by 2028 while private credit defaults threaten portfolio values worldwide.


